The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab Biosimilars
May 16th 2022While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Watch
Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei
May 12th 2022Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Read More
Dr Gillian Woollett Highlights International Markets With Successful Biosimilar Adoption
April 29th 2022Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Watch
Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric Cancer
April 7th 2022A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Read More
Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product
April 7th 2022Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
Watch
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From Originator
March 24th 2022Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Read More
Panel on Prior Authorization Reveals Role PBMs Play in Biosimilar Uptake in Oncology
March 22nd 2022During the recent Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the laser focus on rebates by pharmacy benefit managers (PBMs) may be hindering uptake of biosimilars, thereby keeping some off of formulary lists.
Read More
Julie Reed Previews 2022: The Year of Expanded Access to Biosimilars
March 14th 2022As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
Watch
The Biosimilars Forum's Julie Reed Predicts How Interchangeability Will Impact Biosimilar Uptake
February 25th 2022Julie M. Reed, the new executive director of the Biosimilars Forum, offers her opinion on how interchangeability will impact US biosimilar uptake now that the FDA has given the designation to 2 biosimilars.
Watch
CMS Official Cites OCM as Example of Biosimilar Success
February 21st 2022Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
Read More
VA Study: Patients Switching to Biosimilar Infliximab More Likely to Stop Treatment
February 11th 2022Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.
Read More
Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice
Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.
Read More